Gemella haemolysans cDNA and Antigen

Gemella haemolysans is a Gram-positive bacterium that is part of the normal human oral microbiota, but it can also cause various infections, such as endocarditis, meningitis, and septicemia. One of the surface antigens of Gemella haemolysans is the C protein alpha-antigen (GhCPA), which is a 60 kDa chaperonin that has been shown to have immunostimulatory properties.

GhCPA is a surface-exposed protein that belongs to the chaperonin family of molecular chaperones, which are involved in protein folding and quality control. In Gemella haemolysans, GhCPA has been shown to act as a CD4-T-cell-stimulating antigen, meaning that it can activate immune cells and trigger an immune response.

The implications of GhCPA as a CD4-T-cell-stimulating antigen lie in its potential uses in diagnosis. Because GhCPA can activate immune cells, it can be used as a biomarker for the detection of Gemella haemolysans infections. Several studies have investigated the use of GhCPA as a diagnostic marker for Gemella haemolysans infections, with promising results. For example, one study showed that the detection of antibodies against GhCPA in the serum of patients with endocarditis caused by Gemella haemolysans was highly specific and sensitive, with a diagnostic accuracy of over 90%.

In addition to its potential uses in diagnosis, GhCPA may also have potential as a vaccine candidate for Gemella haemolysans infections. Studies have shown that vaccination with GhCPA can induce a specific immune response and protect against Gemella haemolysans infections in animal models, indicating that this protein may be a potential vaccine target.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Gemella haemolysans cDNA and recombinant antigen can be used in the development of an antigen-based ELISA-based assay for the detection and identification of G. haemolysans in clinical samples. This assay could be used to determine the presence of this species in clinical samples and to monitor the response to treatment protocols. Additionally, the cDNA and recombinant antigen could be used in other research studies involving the study of G. haemolysans, such as gene expression, protein characterization, and other molecular studies.